HHS Drug Pricing Proposals: Some Things Are Off The Table
The US Centers for Medicare and Medicaid Services is proposing an interesting package of innovative pricing policy changes, but some of the topics not included might be as important as the ideas that are.
You may also be interested in...
Medicare Will Test Payment Model For Accelerated Approvals To ‘Expedite’ Confirmatory Trials
The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.
MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.
More Like Untouchable? US Medicare ‘Protected Classes’ Stay Protected – Again
A decision made more than 15 years ago by CMS to require drug insurance plans to cover all drugs for six specific diseases has proven impervious to change. But will the protected classes remain if Part D is reformed more broadly?